Skip to main content

TBPH

Stock
Health Care
Biotechnology

Performance overview

TBPH Price
Price Chart

Forward-looking statistics

Beta
0.84
Risk
41.08%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

theravance biopharma is a biopharmaceutical company with one approved product, vibativĀ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees184
Market cap$426.5M

Fundamentals

Enterprise value$468.8M
Revenue$65.3M
Revenue per employee—
Profit margin-89.38%
Debt to equity29.01

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.18
Dividend per share—
Revenue per share$1.33
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth-0.5
Credit+3.0
Liquidity+1.6
Inflation-2.7
Commodities-0.6
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio185.83
Price to sales8.54
P/E Ratio185.83
Enterprise Value to Revenue7.18
Price to book3.36

Upcoming events

Next earnings dayAugust 5, 2025
Next dividend day—
Ex. dividend day—

News

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.

Zacks Investment Research (June 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free